Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in Guillain-Barré Syndrome
NCT06885762Phase 3Not yet recruiting
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Antibody Fragments
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in Guillain-Barré syndrome (GBS). Primary endpoint: Guillain-Barré Syndrome Disability Scale at 12 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT06885762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06885762.